FOLD - Amicus Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
12/30/2015
Total Revenue
131,416
91,245
36,930
4,958
0
Cost of Revenue
18,076
14,404
6,236
833
-
Gross Profit
113,340
76,841
30,694
4,125
-
Operating Expenses
Research Development
331,018
270,902
149,310
104,793
76,943
Selling General and Administrative
157,513
127,200
88,671
71,151
47,269
Total Operating Expenses
492,950
402,318
241,574
179,186
126,045
Operating Income or Loss
-379,610
-325,477
-210,880
-175,061
-126,045
Interest Expense
24,433
22,402
17,240
5,398
1,578
Total Other Income/Expenses Net
-47,256
-11,671
-225,097
-24,924
-5,424
Income Before Tax
-440,250
-349,089
-449,121
-203,781
-132,118
Income Tax Expense
1,844
-94
-165,119
-3,739
0
Income from Continuing Operations
-442,094
-348,995
-284,002
-200,042
-132,118
Net Income
-442,094
-348,995
-284,002
-200,042
-132,118
Net Income available to common shareholders
-442,094
-348,995
-284,002
-200,042
-132,118
Reported EPS
Basic
-
-1.88
-1.85
-1.49
-1.20
Diluted
-
-1.88
-1.85
-1.49
-1.20
Weighted average shares outstanding
Basic
-
185,790
153,355
134,402
109,924
Diluted
-
185,790
153,355
134,402
109,924
EBITDA
-
-322,471
-428,288
-195,141
-128,707